Spero Therapeutics Inc (SPRO)
1.175
-0.02
(-1.26%)
USD |
NASDAQ |
Nov 22, 16:00
1.175
0.00 (0.00%)
After-Hours: 19:01
Spero Therapeutics Enterprise Value: -11.41M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -11.41M |
| November 20, 2024 | -10.87M |
| November 19, 2024 | -13.05M |
| November 18, 2024 | -14.14M |
| November 15, 2024 | -11.96M |
| November 14, 2024 | -8.142M |
| November 13, 2024 | -4.871M |
| November 12, 2024 | -4.326M |
| November 11, 2024 | -3.781M |
| November 08, 2024 | -4.326M |
| November 07, 2024 | -4.871M |
| November 06, 2024 | -4.871M |
| November 05, 2024 | -5.138M |
| November 04, 2024 | -6.224M |
| November 01, 2024 | -12.20M |
| October 31, 2024 | -9.483M |
| October 30, 2024 | -6.224M |
| October 29, 2024 | -5.138M |
| October 28, 2024 | -6.224M |
| October 25, 2024 | -4.052M |
| October 24, 2024 | -7.854M |
| October 23, 2024 | -7.854M |
| October 22, 2024 | -7.311M |
| October 21, 2024 | -6.768M |
| October 18, 2024 | -6.768M |
| Date | Value |
|---|---|
| October 17, 2024 | -6.496M |
| October 16, 2024 | -8.940M |
| October 15, 2024 | -11.11M |
| October 14, 2024 | -9.483M |
| October 11, 2024 | -8.397M |
| October 10, 2024 | -8.940M |
| October 09, 2024 | -8.940M |
| October 08, 2024 | -8.940M |
| October 07, 2024 | -5.681M |
| October 04, 2024 | -5.681M |
| October 03, 2024 | -6.224M |
| October 02, 2024 | -5.138M |
| October 01, 2024 | -5.138M |
| September 30, 2024 | -3.509M |
| September 27, 2024 | 7.277M |
| September 26, 2024 | 5.656M |
| September 25, 2024 | 5.656M |
| September 24, 2024 | 5.656M |
| September 23, 2024 | 6.737M |
| September 20, 2024 | 8.358M |
| September 19, 2024 | 9.710M |
| September 18, 2024 | 8.899M |
| September 17, 2024 | 8.358M |
| September 16, 2024 | 10.52M |
| September 13, 2024 | 10.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-96.64M
Minimum
Jun 28 2022
527.97M
Maximum
Sep 23 2021
119.20M
Average
41.34M
Median
Enterprise Value Benchmarks
| Arbutus Biopharma Corp | 527.85M |
| Equillium Inc | -0.3668M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.15M |
| Revenue (Quarterly) | 7.819M |
| Total Expenses (Quarterly) | 26.41M |
| EPS Diluted (Quarterly) | -0.32 |
| Profit Margin (Quarterly) | -219.3% |
| Earnings Yield | 6.81% |
| Normalized Earnings Yield | 6.809 |